Original ReportCannabis for the Management of Pain: Assessment of Safety Study (COMPASS)
Key words
Cited by (0)
The study was funded by the Canadian Institutes of Health Research (MOL-66262). M.A.W. receives salary support from the FRQS and the Louise and Alan Edwards Foundation and has a research grant to his institution from CanniMed. M.L. is a founding board member of Panag Pharm Inc, a start-up company researching topical non-psychotropic cannabinoids for pain and inflammation, a medical advisor to Abide Therapeutics researching agents to modulate the endocannabinoid system for the treatment of pain, and a co-investigator on a clinical trial sponsored by Prairie Plant Systems. D.E.M. has received speaker's honoraria and/or consulting fees from Pfizer Canada, Eli Lilly Canada Inc, Janssen Pharmaceuticals, and Purdue Pharma Canada. A.B. discloses consultancies or advisory boards to Bedrocan, CanniMed, Jansen, Johnson & Johnson, Lilly, Merck, Mettrum, Pfizer, and Purdue Pharma. T.W., S.S., J.-P.C., A.G., C.O., and J.M.E. report no conflicts.
Supplementary data accompanying this article are available online at www.jpain.org and www.sciencedirect.com.
- 1
Aline Boulanger, MD, Department d'anesthesie, Université de Montreal, Montreal, Quebec, Canada; John M. Esdaile, MD, Division of Rheumatology, University of British Columbia, Vancouver, British Columbia, Canada; Allan Gordon, MD, Division of Neurology, Mount Sinai Hospital and University of Toronto, Toronto, Ontario, Canada; Mary Lynch, MD, Departments of Anesthesia, Psychiatry and Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada; Dwight E. Moulin, MD, Departments of Clinical Neurological Sciences and Oncology, Western University, London, Ontario, Canada; Colleen O'Connell, MD, Department of Physical Medicine and Rehabilitation, Stan Cassidy Centre for Rehabilitation, Fredericton, New Brunswick, Canada.